Patent ID: 11911455
Assignee: BEIJING AEONVITAL BIOMEDICINE RESEARCH CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 0:
1. A nucleic acid sequence for the treatment and prevention of HPV infection diseases, comprising:
sequence HPV16-AVLS1 and sequence HPV16-AVLC1 in a 1:1 ratio;
and, sequence HPV18-AVLS1 and sequence HPV18-AVLC1 in a 1:1 ratio;
wherein, the sequence AVLS1 and the sequence AVLC1 both include two concatenated protein E6 molecules, two L1 short peptides, two L2 short peptides, two concatenated protein E7 molecules, one PADRE sequence, and one adjuvant sequence; the N-terminal of sequence AVLS1 carries a mouse IgK secretion peptide sequence; the N-terminal of sequence AVLC1 carries a ubiquitin molecule;
in the sequence HPV16-AVLS1 and sequence HPV16-AVLC1, the two L1 short peptides are of the sequences shown in SEQ ID No: 1, SEQ ID No: 2, respectively; the L2 short peptides are of the sequences shown in SEQ ID No: 5, SEQ ID No: 6, respectively;
in the sequence HPV18-AVLS1 and sequence HPV18-AVLC1, the two L1 short peptides are of the sequences shown in SEQ ID No: 3, SEQ ID No: 4, respectively; the L2 short peptides are of the sequences shown in SEQ ID No: 7, SEQ ID No: 8, respectively;
the PADRE sequence is the sequence shown in SEQ ID No: 9;
the adjuvant sequence is the adjuvant peptide Beta-defensin-3, the sequence shown in SEQ ID No: 10;
the mouse IgK secretion peptide sequence is the sequence shown in SEQ ID No: 11;
the sequence of the ubiquitin molecule is the sequence shown in SEQ ID No: 12;
the HPV16 fusion protein E6 sequence introduces C70G and I135T mutations, and the HPV18 fusion protein E6 sequence introduces C65G and I130T mutations;
the HPV16 E7 protein sequence introduces C24G and E26G mutations, and the HPV18 E7 protein sequence introduces C27G and E29G mutations;
the components are connected by AGA or AAY linkers; the adjuvant peptide is connected by a rigid linker EAAAK SEQ ID NO: 19.